Lineage Cell Therapeutics
LCTX
56 hedge funds and large institutions have $63.9M invested in Lineage Cell Therapeutics in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 6 closing their positions.
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.84% less ownership
Funds ownership: 36.82% → 35.98% (-0.84%)
3% less capital invested
Capital invested by funds: $65.6M → $63.9M (-$1.67M)
3% less funds holding
Funds holding: 58 → 56 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
69% less call options, than puts
Call options by funds: $202K | Put options by funds: $654K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$474K |
| 2 |
PAM
Paradigm Asset Management
New York
|
+$330K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$170K |
| 4 |
State Street
Boston,
Massachusetts
|
+$120K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$260K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$141K |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$76K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$74.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$53.5K |
LCTX Hedge Fund Activity: Q3 2013 in Review
56 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2013, worth a combined $63.9M — down 2.5% from $65.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LCTX and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 25 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $474K. The largest seller was Fidelity Investments, cutting an estimated $260K.
- 56 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2013, down from 58 in Q2 2013.
- Funds reported $63.9M of Lineage Cell Therapeutics stock for Q3 2013, down 2.5% quarter-over-quarter.
- 4 funds opened new Lineage Cell Therapeutics positions in Q3 2013 and 6 closed out, a net change of -2 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2013 was BlackRock Fund Advisors, an estimated $474K added.
- The largest Lineage Cell Therapeutics seller in Q3 2013 was Fidelity Investments, an estimated $260K sold.
Based on aggregated 13F filings for Q3 2013.